Melanocyte lineage-specific antigen gp100 is recognized by melanoma- derived tumor-infiltrating lymphocytes (original) (raw)

J Exp Med. 1994 Mar 1; 179(3): 1005–1009.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).

Abstract

We recently isolated a cDNA clone that encodes the melanocyte lineage- specific antigen glycoprotein (gp)100. Antibodies directed against gp100 are an important tool in the diagnosis of human melanoma. Since the gp100 antigen is highly expressed in melanocytic cells, we investigated whether this antigen might serve as a target for antimelanoma cytotoxic T lymphocytes (CTL). Here, we demonstrate that cytotoxic tumor-infiltrating lymphocytes (TIL) derived from a melanoma patient (TIL 1200) are directed against gp100. HLA-A2.1+ melanoma cells are lysed by TIL from this patient. In addition, murine double transfectants, expressing both HLA-A2.1 and gp100, are lysed by TIL 1200, whereas transfectants expressing only HLA-A2.1 are not susceptible to lysis. Furthermore, the HLA-A2.1+ melanoma cell line BLM, which lacks gp100 expression and is resistant to lysis, becomes susceptible after transfection of gp100 cDNA. Finally, HLA-A2.1+ normal melanocytes are lysed by TIL 1200. These data demonstrate that the melanocyte differentiation antigen gp100 can be recognized in the context of HLA-A2.1 by CTL from a melanoma patient. Gp100 may therefore constitute a useful target for specific immunotherapy against melanoma, provided that no unacceptable cytotoxicity towards normal tissue is observed.

Full Text

The Full Text of this article is available as a PDF (439K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Vennegoor C, Hageman P, Van Nouhuijs H, Ruiter DJ, Calafat J, Ringens PJ, Rümke P. A monoclonal antibody specific for cells of the melanocyte lineage. Am J Pathol. 1988 Jan;130(1):179–192. [PMC free article] [PubMed] [Google Scholar]
Adema GJ, de Boer AJ, van 't Hullenaar R, Denijn M, Ruiter DJ, Vogel AM, Figdor CG. Melanocyte lineage-specific antigens recognized by monoclonal antibodies NKI-beteb, HMB-50, and HMB-45 are encoded by a single cDNA. Am J Pathol. 1993 Dec;143(6):1579–1585. [PMC free article] [PubMed] [Google Scholar]
Townsend AR, Rothbard J, Gotch FM, Bahadur G, Wraith D, McMichael AJ. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell. 1986 Mar 28;44(6):959–968. [PubMed] [Google Scholar]
Townsend A, Bodmer H. Antigen recognition by class I-restricted T lymphocytes. Annu Rev Immunol. 1989;7:601–624. [PubMed] [Google Scholar]
Darrow TL, Slingluff CL, Jr, Seigler HF. The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. Evidence for shared tumor antigens. J Immunol. 1989 May 1;142(9):3329–3335. [PubMed] [Google Scholar]
Kawakami Y, Zakut R, Topalian SL, Stötter H, Rosenberg SA. Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas. J Immunol. 1992 Jan 15;148(2):638–643. [PubMed] [Google Scholar]
Anichini A, Maccalli C, Mortarini R, Salvi S, Mazzocchi A, Squarcina P, Herlyn M, Parmiani G. Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients. J Exp Med. 1993 Apr 1;177(4):989–998. [PMC free article] [PubMed] [Google Scholar]
van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991 Dec 13;254(5038):1643–1647. [PubMed] [Google Scholar]
Slingluff CL, Jr, Cox AL, Henderson RA, Hunt DF, Engelhard VH. Recognition of human melanoma cells by HLA-A2.1-restricted cytotoxic T lymphocytes is mediated by at least six shared peptide epitopes. J Immunol. 1993 Apr 1;150(7):2955–2963. [PubMed] [Google Scholar]
Brichard V, Van Pel A, Wölfel T, Wölfel C, De Plaen E, Lethé B, Coulie P, Boon T. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med. 1993 Aug 1;178(2):489–495. [PMC free article] [PubMed] [Google Scholar]
Bean MA, Bloom BR, Herberman RB, Old LJ, Oettgen HF, Klein G, Terry WD. Cell-mediated cytotoxicity for bladder carcinoma: evaluation of a workshop. Cancer Res. 1975 Oct;35(10):2902–2913. [PubMed] [Google Scholar]
Katano M, Saxton RE, Cochran AJ, Irie RF. Establishment of an ascitic human melanoma cell line that metastasizes to lung and liver in nude mice. J Cancer Res Clin Oncol. 1984;108(2):197–203. [PubMed] [Google Scholar]
Eisinger M, Marko O. Selective proliferation of normal human melanocytes in vitro in the presence of phorbol ester and cholera toxin. Proc Natl Acad Sci U S A. 1982 Mar;79(6):2018–2022. [PMC free article] [PubMed] [Google Scholar]
Smit NP, Westerhof W, Asghar SS, Pavel S, Siddiqui AH. Large-scale cultivation of human melanocytes using collagen-coated Sephadex beads (cytodex 3). J Invest Dermatol. 1989 Jan;92(1):18–21. [PubMed] [Google Scholar]
Lin AY, Devaux B, Green A, Sagerström C, Elliott JF, Davis MM. Expression of T cell antigen receptor heterodimers in a lipid-linked form. Science. 1990 Aug 10;249(4969):677–679. [PubMed] [Google Scholar]
te Riele H, Maandag ER, Clarke A, Hooper M, Berns A. Consecutive inactivation of both alleles of the pim-1 proto-oncogene by homologous recombination in embryonic stem cells. Nature. 1990 Dec 13;348(6302):649–651. [PubMed] [Google Scholar]
Graham FL, van der Eb AJ. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology. 1973 Apr;52(2):456–467. [PubMed] [Google Scholar]
Parham P, Brodsky FM. Partial purification and some properties of BB7.2. A cytotoxic monoclonal antibody with specificity for HLA-A2 and a variant of HLA-A28. Hum Immunol. 1981 Dec;3(4):277–299. [PubMed] [Google Scholar]
Parham P, Bodmer WF. Monoclonal antibody to a human histocompatibility alloantigen, HLA-A2. Nature. 1978 Nov 23;276(5686):397–399. [PubMed] [Google Scholar]
Mattes MJ, Thomson TM, Old LJ, Lloyd KO. A pigmentation-associated, differentiation antigen of human melanoma defined by a precipitating antibody in human serum. Int J Cancer. 1983 Dec 15;32(6):717–721. [PubMed] [Google Scholar]
Vijayasaradhi S, Bouchard B, Houghton AN. The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product. J Exp Med. 1990 Apr 1;171(4):1375–1380. [PMC free article] [PubMed] [Google Scholar]
Bystryn JC, Rigel D, Friedman RJ, Kopf A. Prognostic significance of hypopigmentation in malignant melanoma. Arch Dermatol. 1987 Aug;123(8):1053–1055. [PubMed] [Google Scholar]
Richards JM, Mehta N, Ramming K, Skosey P. Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol. 1992 Aug;10(8):1338–1343. [PubMed] [Google Scholar]
Nordlund JJ, Kirkwood JM, Forget BM, Milton G, Albert DM, Lerner AB. Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol. 1983 Nov;9(5):689–696. [PubMed] [Google Scholar]
Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988 Dec 22;319(25):1676–1680. [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press